| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Final version of 2009 AJCC melanoma staging and classification.
|
J Clin Oncol
|
2009
|
23.08
|
|
2
|
A landscape of driver mutations in melanoma.
|
Cell
|
2012
|
12.61
|
|
3
|
Sentinel node biopsy and standard of care for melanoma.
|
J Am Acad Dermatol
|
2009
|
4.32
|
|
4
|
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.
|
Clin Cancer Res
|
2008
|
3.24
|
|
5
|
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).
|
Ann Surg Oncol
|
2010
|
3.02
|
|
6
|
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
|
J Clin Oncol
|
2008
|
2.53
|
|
7
|
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.
|
J Clin Oncol
|
2010
|
2.30
|
|
8
|
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial.
|
Ann Surg
|
2007
|
2.28
|
|
9
|
An evidence-based staging system for cutaneous melanoma.
|
CA Cancer J Clin
|
2004
|
2.18
|
|
10
|
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
|
Clin Cancer Res
|
2004
|
2.05
|
|
11
|
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
|
Ann Surg Oncol
|
2006
|
2.00
|
|
12
|
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
|
Hum Mol Genet
|
2013
|
1.95
|
|
13
|
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).
|
Ann Surg Oncol
|
2012
|
1.92
|
|
14
|
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
|
Oncogene
|
2004
|
1.81
|
|
15
|
Prolonged survival after complete resection of metastases from intraocular melanoma.
|
Cancer
|
2004
|
1.78
|
|
16
|
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes.
|
J Clin Oncol
|
2003
|
1.78
|
|
17
|
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.
|
J Clin Oncol
|
2011
|
1.78
|
|
18
|
CpG island methylator phenotype predicts progression of malignant melanoma.
|
Clin Cancer Res
|
2009
|
1.77
|
|
19
|
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
|
Clin Cancer Res
|
2006
|
1.72
|
|
20
|
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
|
Proc Natl Acad Sci U S A
|
2013
|
1.72
|
|
21
|
Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy.
|
Ann Surg Oncol
|
2002
|
1.65
|
|
22
|
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.
|
Epigenetics
|
2011
|
1.55
|
|
23
|
Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system.
|
JAMA Surg
|
2013
|
1.52
|
|
24
|
Contemporary surgical treatment of advanced-stage melanoma.
|
Arch Surg
|
2004
|
1.52
|
|
25
|
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients.
|
J Clin Oncol
|
2004
|
1.50
|
|
26
|
Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
|
Ann Surg Oncol
|
2004
|
1.44
|
|
27
|
Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications.
|
Cancer J
|
2002
|
1.43
|
|
28
|
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.
|
Ann Surg Oncol
|
2002
|
1.42
|
|
29
|
Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques.
|
Arch Surg
|
2012
|
1.41
|
|
30
|
Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy.
|
Ann Surg Oncol
|
2002
|
1.39
|
|
31
|
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
|
J Clin Oncol
|
2002
|
1.38
|
|
32
|
New TNM melanoma staging system: linking biology and natural history to clinical outcomes.
|
Semin Surg Oncol
|
2003
|
1.34
|
|
33
|
Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node.
|
Mod Pathol
|
2004
|
1.32
|
|
34
|
Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma.
|
Ann Surg
|
2007
|
1.32
|
|
35
|
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.
|
Ann Surg
|
2006
|
1.31
|
|
36
|
Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes.
|
J Surg Oncol
|
2011
|
1.29
|
|
37
|
Prospective multicenter trial of staging adequacy in colon cancer: preliminary results.
|
Arch Surg
|
2006
|
1.28
|
|
38
|
Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?
|
Ann Surg Oncol
|
2009
|
1.25
|
|
39
|
Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
|
Cancer Res
|
2003
|
1.24
|
|
40
|
Endogenous immune response to gangliosides in patients with confined prostate cancer.
|
Int J Cancer
|
2005
|
1.23
|
|
41
|
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors.
|
Mol Cancer Ther
|
2008
|
1.23
|
|
42
|
Age-related lymphatic dysfunction in melanoma patients.
|
Ann Surg Oncol
|
2009
|
1.22
|
|
43
|
The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making.
|
Clin Nucl Med
|
2003
|
1.21
|
|
44
|
Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma.
|
J Clin Oncol
|
2004
|
1.20
|
|
45
|
Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma.
|
Ann Surg Oncol
|
2007
|
1.19
|
|
46
|
Improved survival for stage IV melanoma from an unknown primary site.
|
J Clin Oncol
|
2009
|
1.18
|
|
47
|
Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer.
|
J Clin Oncol
|
2003
|
1.18
|
|
48
|
Late recurrence in melanoma: clinical implications of lost dormancy.
|
J Am Coll Surg
|
2013
|
1.18
|
|
49
|
Estrogen receptor-alpha methylation predicts melanoma progression.
|
Cancer Res
|
2006
|
1.18
|
|
50
|
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.
|
Clin Cancer Res
|
2009
|
1.17
|
|
51
|
Melanoma recurrence patterns after negative sentinel lymphadenectomy.
|
Arch Surg
|
2005
|
1.15
|
|
52
|
Glycoimmunomics of human cancer: current concepts and future perspectives.
|
Future Oncol
|
2007
|
1.14
|
|
53
|
Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma.
|
J Clin Oncol
|
2005
|
1.12
|
|
54
|
Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes.
|
Clin Cancer Res
|
2005
|
1.11
|
|
55
|
Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
|
Cancer Metastasis Rev
|
2006
|
1.11
|
|
56
|
Importance of sentinel lymph node biopsy in patients with thin melanoma.
|
Arch Surg
|
2008
|
1.10
|
|
57
|
AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.
|
J Invest Dermatol
|
2012
|
1.09
|
|
58
|
Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes.
|
Clin Cancer Res
|
2008
|
1.09
|
|
59
|
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
|
Clin Chem
|
2009
|
1.07
|
|
60
|
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.
|
J Invest Dermatol
|
2013
|
1.07
|
|
61
|
Surgery for distant melanoma metastasis.
|
Cancer J
|
2012
|
1.03
|
|
62
|
Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.
|
Int J Cancer
|
2005
|
1.03
|
|
63
|
Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
|
J Clin Oncol
|
2012
|
1.01
|
|
64
|
Vaccine therapy for melanoma: current status and future directions.
|
Vaccine
|
2007
|
1.00
|
|
65
|
Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma.
|
Cancer Res
|
2004
|
1.00
|
|
66
|
Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.
|
J Surg Oncol
|
2010
|
1.00
|
|
67
|
Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma.
|
Clin Cancer Res
|
2007
|
0.99
|
|
68
|
The role of sentinel lymph node biopsy in the management of melanoma.
|
Adv Surg
|
2007
|
0.98
|
|
69
|
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.
|
Cancer Immunol Immunother
|
2003
|
0.98
|
|
70
|
Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.
|
J Immunother
|
2012
|
0.98
|
|
71
|
Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients.
|
J Immunother
|
2007
|
0.98
|
|
72
|
Solitary dermal melanoma: beginning or end of the metastatic process?
|
Ann Surg Oncol
|
2009
|
0.97
|
|
73
|
Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells.
|
Cancer Res
|
2004
|
0.96
|
|
74
|
Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
|
Semin Cancer Biol
|
2003
|
0.95
|
|
75
|
Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.
|
Ann Surg Oncol
|
2007
|
0.95
|
|
76
|
Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
|
J Clin Oncol
|
2002
|
0.94
|
|
77
|
Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.
|
Pigment Cell Melanoma Res
|
2014
|
0.93
|
|
78
|
Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas.
|
J Clin Oncol
|
2003
|
0.93
|
|
79
|
Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
|
J Clin Oncol
|
2003
|
0.92
|
|
80
|
The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions.
|
J Cutan Pathol
|
2010
|
0.92
|
|
81
|
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.
|
Ann Surg Oncol
|
2014
|
0.91
|
|
82
|
Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry.
|
Ann N Y Acad Sci
|
2004
|
0.91
|
|
83
|
The use of molecular profiling of early colorectal cancer to predict micrometastases.
|
Arch Surg
|
2002
|
0.90
|
|
84
|
Predictors of occult nodal metastasis in patients with thin melanoma.
|
Arch Surg
|
2010
|
0.90
|
|
85
|
Age as a prognostic factor in patients with localized melanoma and regional metastases.
|
Ann Surg Oncol
|
2013
|
0.90
|
|
86
|
Can completion lymph node dissection be avoided for a positive sentinel node in melanoma?
|
Ann Surg Oncol
|
2007
|
0.89
|
|
87
|
Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
|
Ann Surg
|
2012
|
0.89
|
|
88
|
Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients.
|
Ann Surg
|
2011
|
0.89
|
|
89
|
Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?
|
Ann Surg
|
2003
|
0.88
|
|
90
|
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
|
J Transl Med
|
2012
|
0.87
|
|
91
|
Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection.
|
Arch Surg
|
2006
|
0.87
|
|
92
|
Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
|
J Immunother
|
2011
|
0.87
|
|
93
|
Unique patterns of metastases in common and rare types of malignancy.
|
J Surg Oncol
|
2011
|
0.86
|
|
94
|
Lymphatic mapping and sentinel lymphadenectomy for primary and metastatic pulmonary malignant neoplasms.
|
Arch Surg
|
2004
|
0.86
|
|
95
|
Androgen blockade enhances response to melanoma vaccine.
|
J Surg Res
|
2003
|
0.86
|
|
96
|
Surgery and sentinel lymph node biopsy.
|
Semin Oncol
|
2007
|
0.85
|
|
97
|
Therapeutic vaccines for melanoma: current status.
|
BioDrugs
|
2005
|
0.85
|
|
98
|
Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment.
|
Am Surg
|
2003
|
0.85
|
|
99
|
Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma.
|
Ann Surg Oncol
|
2009
|
0.84
|
|
100
|
A novel lymphatic mapping technique to improve localization and staging of early colon cancer during laparoscopic colectomy.
|
Am Surg
|
2002
|
0.84
|
|
101
|
Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.
|
J Invest Dermatol
|
2010
|
0.83
|
|
102
|
A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
|
Cancer Invest
|
2007
|
0.83
|
|
103
|
Management of popliteal sentinel nodes in melanoma.
|
J Am Coll Surg
|
2011
|
0.82
|
|
104
|
Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread.
|
Clin Exp Metastasis
|
2012
|
0.82
|
|
105
|
Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM.
|
Cryobiology
|
2002
|
0.82
|
|
106
|
Epitrochlear sentinel lymph nodes in melanoma: interval or independent?
|
Am Surg
|
2012
|
0.81
|
|
107
|
Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer.
|
Biochem Biophys Res Commun
|
2004
|
0.80
|
|
108
|
Human antiganglioside autoantibodies: validation of ELISA.
|
Ann N Y Acad Sci
|
2005
|
0.79
|
|
109
|
Combination probe and dye-directed lymphatic mapping detects micrometastases in early colorectal cancer.
|
J Gastrointest Surg
|
2003
|
0.79
|
|
110
|
Staging of regional nodes in pulmonary malignancies.
|
Ann Surg Oncol
|
2012
|
0.78
|
|
111
|
Serum total ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine.
|
J Immunother
|
2003
|
0.78
|
|
112
|
Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes?
|
Cancer J
|
2006
|
0.78
|
|
113
|
Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma.
|
Ann Surg Oncol
|
2002
|
0.78
|
|
114
|
One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastases.
|
J Gastrointest Surg
|
2002
|
0.78
|
|
115
|
High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma.
|
Pigment Cell Melanoma Res
|
2009
|
0.77
|
|
116
|
Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.
|
J Am Coll Surg
|
2004
|
0.77
|
|
117
|
Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
|
J Clin Oncol
|
2003
|
0.77
|
|
118
|
Melanoma: is immunotherapy of benefit?
|
Adv Surg
|
2003
|
0.77
|
|
119
|
Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III Melanoma.
|
Ann Surg Oncol
|
2004
|
0.77
|
|
120
|
Sentinel node biopsy: facts to clear the alleged clouds.
|
Arch Dermatol
|
2008
|
0.76
|
|
121
|
Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy.
|
Ann N Y Acad Sci
|
2007
|
0.76
|
|
122
|
Immunotherapy of malignant melanoma.
|
Surg Clin North Am
|
2003
|
0.76
|
|
123
|
Immunogenic gangliosides in human ovarian carcinoma.
|
Biochem Biophys Res Commun
|
2006
|
0.76
|
|
124
|
Management decisions for nodal metastasis from an unknown primary melanoma.
|
Am J Hematol Oncol
|
2008
|
0.75
|
|
125
|
Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study.
|
Curr Surg
|
2005
|
0.75
|
|
126
|
Detection of clinically relevant melanoma metastases requires focused, not exhaustive, evaluation of sentinel lymph nodes.
|
Am J Surg Pathol
|
2006
|
0.75
|
|
127
|
The promise of metastasectomy in melanoma.
|
Ann Surg Oncol
|
2006
|
0.75
|
|
128
|
Immunotherapy today: the story of a vaccine.
|
J Drugs Dermatol
|
2005
|
0.75
|
|
129
|
Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer.
|
Cancer J
|
2002
|
0.75
|
|
130
|
In honor of Alfred Schutt Ketcham, M.D.
|
J Surg Oncol
|
2007
|
0.75
|
|
131
|
Annals of surgical oncology impact factor/rating has dramatically increased.
|
Ann Surg Oncol
|
2003
|
0.75
|